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Cytogenetic and molecular studies have identified genetic alter-
ations on chromosome 11p as one of the most frequent events
during the progression of bladder cancer (Habuchi et al, 1993;
Shaw and Knowles, 1995; Voorter et al, 1996; Gibas and Gibas,
1997). Deletion mapping has revealed a common region of
deletion between D11S922 (11p15.5) and D11S569 (11p15.1–
11p15.2), but it is not yet known which particular gene constitutes
the relevant target. This region contains several imprinted genes.
Among these, IGF2 and  H19 have already been implicated in
urothelial carcinoma (Elkin et al, 1995; Cooper et al, 1996), but
the KIP2 (CDKN1C) gene from the same imprinted region is a
further attractive candidate.
The  KIP2 gene is expressed from the maternal allele and
encodes the p57KIP2 protein, a member of the p21CIP1 cyclin-depen-
dent kinase inhibitor family inhibiting the G1 → S transition of the
cell cycle (Lee et al, 1995; Matsuoka et al, 1995; Hatada et al,
1996; Matsuoka et al, 1996). Accordingly, the p57KIP2 protein
blocks cell proliferation when expressed in several types of
cultured cells (Lee et al, 1995; Matsuoka et al, 1995; Reid et al,
1996). During development, it acts in concert with other CDK
inhibitors to control tissue growth and development (Zhang et al,
1998). Some evidence implicates KIP2 in Beckwith-Wiedemann
syndrome (BWS), but alterations in IGF2 have also been found
(Reik et al, 1995; Lee et al, 1997; O’Keefe et al, 1997). BWS
patients are predisposed to certain childhood cancers such as
Wilms’ tumour and rhabdomyosarcoma, in accord with the idea
that p57KIP2 might act as a tumour suppressor. Decreased expres-
sion of p57KIP2 due to loss of the maternal allele or aberrant
imprinting has indeed been reported in some Wilms’ tumours
(Hatada et al, 1996) and in individual cases point mutations have
been found (O’Keefe et al, 1997). Northern analysis has shown
p57KIP2 to be expressed in specific adult tissues such as heart,
brain, skeletal muscle, kidney, pancreas and testis, but not in lung
and liver (Lee et al, 1995). Decreased expression has been
reported in lung (Kondo et al, 1996) and adrenal (Liu et al, 1997)
cancers. Expression in bladder cancer has not yet been studied.
The product of the IGF2 gene, expressed from the paternal
allele, acts as an autocrine or paracrine growth factor and its over-
expression could therefore contribute to tumour growth. For
instance, overexpression of IGF2 through biallelic expression
caused by loss of imprinting has been identified as an early change
in the development of Wilms’ tumours (Ogawa et al, 1993; Rainier
et al, 1993; Weksberg et al, 1993; Steenman et al, 1994; Moulton
et al, 1994; Taniguchi et al, 1995; Okamoto et al, 1997), but has
also been observed in bladder cancer (Elkin et al, 1995). The H19
gene, expressed from the maternal allele, encodes an RNA abun-
dant in foetal tissues during development, but with a low level in
adult tissues. The physiological role of H19 RNA is not clear.
Although tumour suppressor activity was suggested by studies on
cell lines derived from Wilms’ tumours (Reid et al, 1996), other
results do not fit this hypothesis (Leighton et al, 1995).
Overexpression of H19 RNA as detected by in situ hybridization
has been reported in high-grade invasive bladder cancer (Cooper
et al, 1996).
The regulation of the genes in the imprinted region on chromo-
some 11p15.5 has turned out to be extremely complex. Most
recently, an imprinting centre was identified within the KvQLT
gene that is thought to control the expression of KIP2 and several
other genes on the centromeric side of KvQLT, but not of the
telomeric H19 and IGF2 genes (Lee et al, 1999; Smilinich et al,
1999). Therefore, altered expression of KIP2 could not only be
due to loss of the gene itself, but also to changes in distant
segments of DNA on the same chromosome. In addition, loss of
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prevalent in bladder cancers (Jürgens et al, 1996). Again, this may
occur at the KIP2 locus itself or at a distinct control region (Dao et
al, 1999).
Since however, for each of the three genes, deletions as well as
epigenetic changes would be expected to affect their mRNA
levels, we decided to study expression at this level by quantitative
RT-PCR in a series of bladder carcinomas and corresponding
normal tissue to elucidate which of them might represent a crucial
target during bladder cancer progression.
MATERIALS AND METHODS
Tissue specimens
Twenty-four paired samples of tumour and normal tissue were
obtained from patients undergoing radical cystectomy. From the
cystectomy specimens paired samples of urothelial carcinoma and
morphologically normal mucosa were identified, immediately cast
in liquid nitrogen and stored at –80° C. Patient data and tumour
characteristics are listed in Table 1. All tumours were transitional
cell carcinomas of the urinary bladder. Grading and staging were
performed according to the TNM classification (UICC).
Cell lines
The human bladder cancer cell lines, J82, VMCubI, VMCubII,
VMCubIII, T24, 647V, 5637, HT1376, RT-4, 639V, TCCsup,
SW1710, 253J and BFTC909 were cultured as described previ-
ously (Grimm et al, 1995).
RNA extraction
Total RNA was prepared from pre-confluent cell monolayers or
frozen tissue by guanidinium/acid phenol/chloroform extraction
(TRIzolReagent, Life Technologies, Berlin, Germany) as suggested
by the supplier. Following re-extraction with chloroform and
precipitation with isopropanol, RNA was re-dissolved in diethyl
pyrocarbonate-treated water and quantified by spectrophotometry.
Reverse transcription and PCR
Quantitative analysis of mRNA levels was performed essentially
as described (Clasen et al, 1998; Oya et al, 1998). Primer
sequences and amplification conditions are listed in Table 2. For
quantitative analysis, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA was co-amplified as an internal control and each
reaction was performed within the linear phase of amplification.
Each reaction was begun with an initial cycle of 5 min denatura-
tion at 96° C, 5 min at the specific annealing temperature, and 90 s
extension at 72° C, followed by the indicated number of definitive
cycles of 96° C for 30 s, the specific annealing temperature for 45
s, and 72° C for 90 s. A final extension was performed at 72° C for
10 min. PCR products were separated on a 2% agarose gel before
overnight transfer to a nylon membrane (Hybond-N+, Amersham,
UK). Following detection with alkaline phosphatase-conjugated
anti-digoxigenin antibody (Boehringer-Mannheim, Germany)
luminescence signals were quantified from appropriately exposed
films by video densitometry (ONE-D-SCAN 1.0, Scanalytics,
MA). Values were related to GAPDH and are expressed as
arbitrary expression units (AU) calculated as each gene
signal/GAPDH signal. At least two independent measurements
were performed for each sample and at least four for all deviating
from the normal value. Analyses for intragenic polymorphisms
were performed as described (Tadokoro et al, 1991).
DNA extraction and LOH analysis
DNA was extracted and characterized from powdered frozen
tissues or from leukocytes as described (Jürgens et al, 1996;
Schulz et al, 1997). Two microsatellite markers, D11S1318 and
D11S922, were used for LOH analysis. Primer sequences were
obtained from the Genome Data Base. Each sense primer was
marked with IRD-800 at the 5′ -nucleotide. PCR was carried out in
50 µ l reactions using 100 ng DNA each from tumours and corre-
sponding leukocytes. Reaction conditions were 95° C for 5 min,
followed by 32 cycles of 94° C for 1 min, 61° C (D11S1318) or
56° C (D11S922) for 1 min and 72° C for 2 min. The final extension
was at 72° C for 10 min. One µ l of diluted PCR product was loaded
on 6% DNA sequencing gels in 1 × TBE buffer on a LI-COR auto-
mated sequencer. The ratio of alleles was calculated for each pair
of normal and tumour samples using ONE-D-SCAN 1.0 software
(Scanalytics, MA, USA) following the procedure described by An
et al (1996).
RESULTS
p57KIP2 mRNA expression in bladder cancer and cell
lines
Expression of p57KIP2 mRNA relative to GAPDH mRNA as
measured by quantitative RT-PCR (Table 1, Figure 1) was dimin-
ished in bladder cancer tissues compared to normal mucosa: 
0.82 ± 0.49 vs 1.24 ± 0.58 AU (n = 24), but the difference was not
statistically significant. Expression in normal mucosa ranged 
from 0.57–2.87 AU and in tumours from 0.01–1.62 AU.
Overexpression defined as a more than two-fold increase over the
level found in corresponding normal mucosa was neither observed
in primary tumours nor in bladder cancer cell lines. Loss of expres-
sion defined as less than 10% expression compared to normal
mucosa was observed in four tumours (4/24 = 17%) and in 5/14
(29%) cell lines (Table 3). Diminished expression, defined as from
10–50% of that in corresponding normal mucosa, was observed in
five patients. In six cell lines, mRNA levels from 10–50% of
average normal mucosa were measured. Therefore, overall,
expression of p57KIP2 mRNA was significantly decreased in nine
patients (9/24 = 38%) and in eight cell lines (11/14 = 79%).
Among the tumour tissues, no association of decreased expression
with tumour stage or grade was apparent. In particular, loss of
expression was found in several tumours of comparatively low
stage or grade (Table 1). However, in this regard the data is skewed
towards invasive, high-grade tumours and needs to be considered
with caution.
IGF2 mRNA expression in bladder cancer and in
bladder cancer cell lines
The average expression level of IGF2 mRNA relative to GAPDH
mRNA (Table 1, Figure 1) was almost identical between cancer
tissues and normal mucosa: 1.18 ± 1.27 vs 1.19 ± 0.63 AU (n = 24).
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from 0.01–2.03 in cancer tissue. In one bladder tumour (#24) and
in the corresponding morphologically normal mucosa, IGF2
mRNA was found to be overexpressed 5.5-fold and 2.7-fold,
respectively. This patient was heterozygous at the Apa I site in the
IGF2 gene, and expression was found to be biallelic in tumour as
well as in mucosa tissue. Overexpression of IGF2 mRNA also
occurred in the cell lines T24 and HT1376 (Table 3). Loss of IGF2
mRNA expression was observed in two patients (2/24 = 8%) and
in eight cell lines (8/14 = 57%). Diminished expression was
observed in three patients and in one cell line (Figure 1). Overall,
IGF2 mRNA expression was decreased in five patients (5/24 =
21%) and in nine cell lines (9/14 = 64%). No correlation of altered
IGF2 expression with tumour stage or grade was evident.
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Table 1 Expression of 11p15.5 genes in bladder carcinomas (A) Clinical data, (B) results
No Age Sex Tumour Lymph node Tumour
Stage status grade
1 57 M pT2 pN0 2
2 62 M pT3a pN0 2
3 60 F pT3b pN2 3
4 60 M pT3b pN2 3
5 60 M pT1 pN0 2
6 74 M pT3b pN0 2
7 68 F pT3a pN0 3
8 78 M pT4 pN1 3
9 77 M pT3b pN0 3
10 61 M pT1 pN0 3
11 66 F pT1 pN0 3
12 72 M pT2 pN0 3
13 73 F pT4 pN2 3
14 56 M pT2 pN0 3
15 59 M pT4 pN0 3
16 70 M pTa pN0 2
17 60 M pT3b pN0 3
18 66 M pT3b pN2 3
19 75 F pT2 pN0 2
20 66 M pTa pN0 2
21 69 M pT2 pN0 3
22 70 M pT2 pN0 3
23 65 M pT2 pNx 3
24 64 M pT3b pN1 3
No p57 IGF-II H19 LOH
N T T:N N T T:N N T T:N D11S922 D11S1318
1 1.93 1.34 0.69 1.20 1.05 0.88 1.60 1.11 0.69 NI RET
2 0.97 1.25 1.29 1.90 1.67 0.88 1.37 1.60 1.17 RET RET
3 2.87 0.88 0.31 1.22 2.03 1.66 1.61 1.21 0.75 MI RET
4 0.94 0.02 0.02 0.63 1.06 1.68 0.95 0.05 0.05 n.d. n.d.
5 0.95 0.58 0.59 1.79 0.50 0.33 0.94 1.10 1.17 NI LOH
6 1.10 1.25 1.14 1.79 1.51 0.84 1.12 1.10 0.98 RET RET
7 1.88 0.97 0.52 1.17 1.62 1.38 1.50 0.85 0.57 NI LOH
8 1.13 1.46 1.29 0.49 0.45 0.92 1.34 1.35 1.01 NI NI
9 1.33 0.04 0.03 1.23 0.01 0.01 1.29 2.17 1.68 RET LOH
10 0.69 0.73 1.06 1.08 1.30 1.20 0.96 0.61 0.64 n.d. n.d.
11 0.90 0.07 0.08 0.90 0.68 0.76 0.78 0.01 0.01 NI NI
12 1.00 1.01 1.01 0.48 0.44 0.92 1.30 0.98 0.75 n.d. n.d.
13 1.01 0.41 0.41 0.50 0.47 0.94 0.42 0.22 0.52 n.d. n.d.
14 1.24 1.61 1.30 0.51 0.42 0.82 1.12 1.70 1.52 RET NI
15 1.35 1.20 0.96 1.65 1.11 0.67 1.75 0.90 0.51 RET RET
16 0.60 0.01 0.02 1.05 0.18 0.17 0.85 0.04 0.04 LOH LOH
17 2.55 1.17 0.46 2.12 0.91 0.43 1.25 1.28 0.89 RET NI
18 0.87 0.81 0.93 1.11 1.25 1.13 0.74 0.99 1.34 RET RET
19 0.96 0.40 0.42 0.71 1.04 1.46 0.55 2.02 3.67 LOH LOH
20 0.69 0.57 0.83 0.77 1.33 1.82 1.15 1.18 1.03 LOH NI
21 0.57 0.60 1.05 0.91 1.00 1.10 1.09 1.29 1.18 RET LOH
22 1.44 1.02 0.71 0.79 0.03 0.04 0.90 0.84 0.93 RET RET
23 1.24 1.62 1.31 1.33 1.76 1.32 0.95 0.98 1.03 n.d. n.d.
24 1.58 0.74 0.47 3.17 6.53 2.06 1.04 1.16 1.12 RET RET
N, T: mRNA expression (AU) in normal and tumour tissue, respectively; T:N quotient: bold letters mark deviating samples, italics those
with overexpression. LOH: results of LOH analysis, LOH = loss of heterozygosity; RET: retention; NI: not informative; MI: microsatellite
instability; n.d.: not done because DNA was unavailableH19 RNA expression in bladder cancer and in bladder
cancer cell lines
Average expression of H19 RNA relative to GAPDH mRNA
(Table 1, Figure 1) was very similar in cancer tissues and normal
mucosa: 1.03 ± 0.56 vs 1.11 ± 0.33 AU (n = 24). Expression
ranged from 0.42–1.75 AU in normal mucosa and from 0.01–2.17
AU in tumours. Moderate overexpression compared to the corre-
sponding normal mucosa was observed in one bladder cancer
specimen (#19). The patient was unfortunately homozygous for
the intragenic Rsa I polymorphism. The cell line HT1376 also
displayed an increased level of H19 RNA (Table 3). Loss of H19
mRNA expression (cf. Figure 1) was observed in only three
tumours (3/24 = 13%) of different stages and grades, but in seven
cell lines (7/14 = 50%). No tumours with a level of expression
between 10–50% of that in normal mucosa were observed, but the
two cell lines VMCubI and 639V showed expression levels in this
range.
Correlation of expression changes
All three patients with loss of H19 RNA expression had concomi-
tantly lost p57KIP2 mRNA expression whereas decreased expression of
p57KIP2 mRNA was observed more frequently without concomitant
changes in H19. The two tumours overexpressing either H19 or IGF2
mRNA had diminished expression of p57KIP2 mRNA. Likewise, the
cell line HT1376 overexpressing IGF2 and H19 mRNAs displayed
loss of p57KIP2 expression and the cell line T24, with a two-fold over-
expression of IGF2 mRNA, showed decreased expression of p57KIP2
mRNA. Among the five patients with decreased expression of IGF2
mRNA, three had concomitantly decreased p57KIP2 mRNA, but in two
of them it was the sole alteration. Among the cell lines, the former
situation was rather frequent, being present, e.g. in J82, VmCub1, and
639V, whereas an isolated decrease in IGF2 mRNA was found only in
the black-foot disease cell line BFTC909. Notably, decreased expres-
sion of IGF2 mRNA was not associated with increased expression of
H19 RNA or vice versa in either primary tumours or cell lines.
Among the nine tumours with decreased p57KIP2 mRNA levels, six
displayed a concomitant decrease of IGF2 and/or H19 expression, but
three patients showed this as the only alteration. Of note, one papillary
tumour and the papillary tumour RT4 cell line as well as the cell line
TCCsup showed an almost complete loss of expression of all three
mRNAs.
Loss of heterozygosity
Loss of heterozygosity (LOH) analysis was performed to estimate
its frequency in the samples investigated. DNA suitable for LOH
analysis was available from 20 of the 24 tumours and corre-
sponding leukocytes. Two microsatellites on chromosome 11p15.5,
D11S1318 located between the KIP2 and IGF2 loci and D11S928
telomeric to the H19 locus, were investigated. Eighteen tumours
were informative for at least one marker, seven of which (39%)
showed loss of heterozygosity at one locus (Table 1). LOH was
detected in 4/14 (28%) informative samples at D11S1318 and in
4/12 (33%) informative samples at D11S922, respectively. One
tumour DNA (#3) yielded additional bands at D11S1318 suggestive
of microsatellite instability. Four instances of LOH (tumours #5, 9,
16, 19) were associated with expression changes in at least one of
the genes, one tumour (#7) with LOH displayed borderline expres-
sion of KIP2 and H19, but two instances (#20, #21) occurred in
tumours with evidently normal expression of all three genes.
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Table 2 PCR conditions used
Gene Sequence of primers Annealing Cycles Amplicon size Extras
(sense/antisense) temperature (° C) (bps)
p57 5′ -GCGGCGATCAAGAAGCTGTC-3′ 60 27 269 hot start
5′ -CCGGTTGCTGCTACATGAAC-3′ 6% DMSO
IGF-II 5′ -CATTGCTTACCGCCCCAG-3′ 62 23 200 2% formamide
5′ -AGTACGTCTCCAGGAGGGCC-3′
H19 5′ -TACAACCACTGCACTACCTG-3′ 61 21 575 3% formamide
5′ -TGGAATGCTTGAAGGCTGCT-3′
GAPDH 5′ -TCCCATCACCATCTTCCA-3′ 60–62 17 380 accordingly
5′ -CATCACGCCACAGTTTCC-3′ as above
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Figure 1 Expression of 11p15.5 genes in urothelial carcinoma. The figure
shows typical luminographs from quantitative RT-PCR analyses of p57KIP2
(top), IGF-II (middle), and H19 (bottom) mRNA levels in cell lines (left) and
normal (N) or urothelial tumour (T) tissues (right). GAPDH mRNA was used
for comparison throughout all experiments. The sizes of the PCR products
are indicated on the right-hand side. The cell lines used were: (1) VMCub III;
(2) T24; (3) J82; (4) 647V; (5) 5637; (6) HT1376. The indicated tissue
numbers correspond to those in Table 1. Note that the top panel displays
results from two separate experiments (as evident from the different
backgrounds)DISCUSSION
The central issue addressed in this study was whether the KIP2 gene
might be a target of genetic and/or epigenetic alterations on chromo-
some 11p15.5 in progressive bladder cancers. Since either deletions,
altered DNA methylation or loss of imprinting would be expected to
result in altered levels of mRNA, we approached this question by
comparing mRNA levels in paired tumour and normal mucosa
samples. Indeed, more than one third of the primary tumours in our
study (9/24 = 38%) and even more of the bladder cancer cell lines
(11/14 = 79%) showed substantially decreased p57KIP2 mRNA
expression. Importantly, several specimens displayed complete loss
of expression. Previous studies have consistently estimated the
frequency of LOH on chromosome 11p15.5 in advanced bladder
cancers as being 30–40%. The frequency of LOH in the present
study (at least 33%) was within this usual range. Thus, the observed
frequency of altered p57KIP2 expression was that expected for a
tumour suppressor gene targeted by alterations in the chromosome
11p15.5 region. It remains possible that in addition to decreased
expression, point mutations contribute to loss of p57KIP2 function in
bladder cancers, even though no mutations were found in 20
tumours studied by Tokino et al (1996).
Two further imprinted genes from the same chromosomal
region, IGF2 and H19, are thought to be involved in growth regu-
lation and have already been shown to be overexpressed in some
urothelial carcinomas (Elkin et al, 1995; Cooper et al, 1996).
Altered expression of these two genes was less frequent in primary
tumours, but also highly prevalent in bladder tumour cell lines. It
is important to note that with our method both tumours with over-
expression and decreased expression of IGF2 or H19 mRNA were
observed. In contrast, expression of KIP2 was never increased.
Significantly, loss of H19 expression was found in primary
tumours only in association with loss of KIP2 expression. Since
H19 RNA is maternally expressed like p57KIP2, the concomitant
loss of expression of both genes in several tumours could be due to
deletions affecting the maternal chromosome. Therefore, loss of
H19 gene expression may be secondary to loss of KIP2.
Nevertheless, decreased expression of KIP2 is certainly only
one among several consequences of alterations involving the chro-
mosome 11p15.5 region. Two primary tumours (#5 and 22) and
one cell line (647V) showed substantially decreased expression of
IGF2 mRNA associated with borderline (#5) or normal expression
(#22) of p57KIP2 mRNA. Several tumours, and less surprisingly
most cell lines, presented multiple changes suggesting involve-
ment of the chromosomes 11 from both parents. For instance,
decreased expression of p57KIP2 as well as IGF2 mRNAs was
found repeatedly (#9, #17, J82, VMCubI and 639V), occasionally
accompanied by loss of H19 expression as well (#16, RT-4 and
TCCsup). Our study also confirms that biallelic expression of
IGF2 occurs in bladder cancer. In one case it was observed in both
tumour and morphologically normal mucosa (patient #24) and
may represent an early alteration as suggested (Elkin et al, 1995).
While overexpression of IGF2 has been identified in many
different cancers (McCann et al, 1996; Mori et al, 1996; Uyeno et
al, 1996; Nonomura et al, 1997; Oda et al, 1998) and could there-
fore also contribute to bladder cancer development, it is difficult to
conceive how loss of its expression might have the same effect.
Nevertheless, loss of IGF2 expression in tumour tissues and cell
lines indicates that not only expression from the maternal, but also
the paternal chromosome is disturbed in advanced bladder
cancers. Moreover, almost none of the bladder carcinoma cell lines
showed an expression pattern comparable to normal mucosa.
Therefore, our data are best explained by assuming that the KIP2
gene is an important target of genetic or epigenetic alterations on
chromosome 11p15.5 in bladder cancer, but that during tumour
progression often both chromosomes are affected. Several appar-
ently independent changes have also been identified in this region
in several other tumours (summarized in Karnik et al, 1998). It is
therefore conceivable that the high frequency and variety of
changes observed in this chromosomal region indicate that it is
particularly susceptible to damage resulting from genomic insta-
bility in progressive tumours.
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